ScreenerHero

ASND Ascendis Pharma A/S

NAS · US · Healthcare · Biotechnology · ascendispharma.com
228.03USD+0.07%Mkt Cap: 15.01B $P/E: 17.47

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD
TWST
Twist Bioscience Corporation
$13.59BUSD

Key Statistics

Company
Market Cap15.01B USD
Enterprise Value14.60B USD
Revenue (TTM)1.05B USD
Gross Profit625.22M USD
Net Income (TTM)-228.03M USD
Revenue/Share16.89 USD
Last Price228.03 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.2K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)17.47
P/E (Forward)21.04
PEG—
EV/EBITDA55.43
EV/Revenue13.95
P/S14.32
P/B9.26
EPS (TTM)13.05
EPS (Forward)10.83
52W Range
186.0547% of range274.89
52W High274.89 USD
52W Low186.05 USD
Profitability
Gross Margin86.82%
Oper. Margin64.98%
EBITDA Margin25.16%
Profit Margin-31.67%
ROE140.05%
ROA-17.51%
Growth
Revenue Growth114.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF53.90M USD
CapEx (TTM)8.48M USD
FCF Margin1.22%
FCF Yield0.09%
Net Debt-362.19M USD
Net Debt/EBITDA-1.37
Balance Sheet
Debt/Equity-5.35
Current Ratio2.99
Quick Ratio2.23
Book Value/Sh24.62 USD
Cash/Share12.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)307.18 USD
Upside (mean)+34.7%
Target Range263.13 USD – 351.09 USD
263.13+34.7% to mean351.09
# Analysts20
Ownership
Shares Out.65.80M
Float65.64M
Insiders0.78%
Institutions104.04%
Short Interest
Short Ratio6.3d
Short % Float7.13%
Short % Out.6.02%
Shares Short3.96M
Short (prev mo.)3.69M
Technical
SMA 50248.70 (-8.3%)
SMA 200235.57 (-3.2%)
Beta—
S&P 52W Chg14.58%
Avg Vol (30d)668.62K
Avg Vol (10d)803.80K
Technical Indicators
RSI (14)39.7
MACD-6.4640
MACD Signal-4.6094
MACD Hist.-1.8546
BB Upper279.00 USD
BB Middle243.12 USD
BB Lower207.25 USD
BB Width29.51%
ATR (14)8.124 USD
Vol Ratio (20d)1.02x